Garen Serafian
Vice President of Investor Relations
Replay available
Bausch Health Companies Inc. (NYSE: BHC) Q1 2026 earnings conference call, held 2026-04-29. Replay captured from the company's public earnings webcast.

Vice President of Investor Relations
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer and Head of Research and Development
Analyst, RBC Capital Markets
Analyst, Evercore ISI
Analyst, TD Cal
Greetings, and welcome to the Bausch Health First Quarter twenty twenty six Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star, one on your telephone keypad. It's now my pleasure to turn the call over to Garen Vice President, Investor Relations. Garen, please go ahead. Good afternoon and welcome to Bausch Health's first quarter twenty twenty six earnings conference call. My name is Garen Serafian, Vice President of Investor Relations. Participating in today's call are Thomas Appio, Chief Executive Officer JJ Charon, Chief Financial Officer and Johnson Sadeh, Chief Medical Officer and Head of Research and Development. Before we begin, I would like to remind you that today's presentation contains forward looking information. Please take a moment to review the forward looking statements disclaimer at the beginning of the slides accompanying this presentation as it contains important information. Actual results may differ materially from those expressed or implied in these forward looking statements and you should not place undue reliance on them. Please also refer to our SEC filings and our filings with the Canadian Securities Administrators for a discussion of certain risk factors that could cause actual results to differ materially from expectations. We use non GAAP financial measures to help investors better understand our operating performance. These non GAAP measures may not be comparable to similarly titled measures used by other companies and should be considered in addition to and not as a substitute for measures calculated in accordance with GAAP. Reconciliations to our non GAAP measures are inclu...